LONDON, UK / ACCESSWIRE / January 15, 2021 / After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues to show a consistent and robust, sustained average gain in visual acuity in retinitis pigmentosa (RP). A continuation study in nine patients using two million cells is underway with three- and six-month data due over H2 CY21 and the first three patients treated. This will facilitate partnering negotiations. A pivotal hRPC study may start in 2022. Deals are possible in CY21 on the exosome genetic drug delivery platform, which could be very valuable. The valuation remains at £190m with strong cash.

ReNeuron conducted a placing of £15m and open offer of £2.5m in late 2020, giving £17.5m gross. Management states that this cash will cover costs for at least 18 months. Our indicative value is unchanged at £190m. We note current high deal values in the gene and cell retinal therapy area, with one totalling $250m plus royalties in June. Exosome projects are promising but are preclinical and need partners to progress into development; many deals have been at high values. In October 2020, Codiak, a pure exosome company with two clinical projects, completed a US IPO and is now valued at about $590m.

Click here to view the full report.

Subscribe to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Dr John Savin +44 (0)20 3077 2500
[email protected]

Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv

SOURCE: Edison Investment Research Limited